What is the 13F Pro Quality Score for NRXP?

13F Pro ranks NRX Pharmaceuticals, Inc. (NRXP) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View NRXP's current score at https://13fpro.ai/company/NRXP (free sign-up required for the full ranking).

Which hedge funds own the most NRXP stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of NRXP include B Group,, VANGUARD CAPITAL MANAGEMENT, AMERIPRISE FINANCIAL. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/NRXP as soon as new 13F filings post.

Where does 13F Pro source NRXP data?

All NRX Pharmaceuticals, Inc. fundamentals and ownership data come directly from SEC EDGAR. NRX Pharmaceuticals, Inc. files with the SEC under CIK 1719406. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is NRXP in?

NRX Pharmaceuticals, Inc. (NRXP) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is NRXP research updated on 13F Pro?

NRXP's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

NRX Pharmaceuticals, Inc.(NRXP)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1719406 NRXP stock profile & AI dashboard →

13F Pro Quality Score

21.0/100

Rank #2,771 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why NRXP Scores 21/100

exact factor attribution · 2026-09-11

NRXP's composite is driven by earnings growth and institutional flow, held back by scale and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Earnings growth

+2.2 pts

95th pct

Institutional flow

+1.9 pts

88th pct

Shareholder dilution

-1.8 pts

14th pct

Earnings quality

-2.6 pts

24th pct

Revenue growth

-4.0 pts

30th pct

Capital efficiency

-4.7 pts

3th pct

Profitability

-6.5 pts

7th pct

Free cash flow

-6.6 pts

6th pct

Scale

-6.9 pts

4th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

NRXP Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for NRX Pharmaceuticals, Inc. (NRXP), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NRXP at 21.0/100 on a 32-signal composite quality model, placing it at rank #2,771 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), NRX Pharmaceuticals, Inc. reports quarterly revenue of $1.1M, net income of $-16.5M. Top institutional holders of NRXP by reported 13-F value include B Group, VANGUARD CAPITAL MANAGEMENT, AMERIPRISE FINANCIAL, based on the most recent SEC filings. NRXP trades on the Nasdaq exchange and files with the SEC under CIK 1719406. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NRXP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NRX Pharmaceuticals, Inc. directly from SEC EDGAR. NRX Pharmaceuticals, Inc.'s 13F Pro composite quality score has ranged between 14 and 21 since 2026, currently 21.0 — an improving long-term trajectory across 8 quarterly and live scoring snapshots.

Revenue

Q2 2026

$1.1M

Net Income

Q2 2026

$-16.5M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

$1.2MFY 2025

FY22 —FY23 $0.00FY24 $0.00FY25 $1.2M

Net Income

-13.9% YoY

$-28.6MFY 2025

FY22 $-39.8MFY23 $-30.1MFY24 $-25.1MFY25 $-28.6M

Operating Income

+12.3% YoY

$-16.2MFY 2025

FY22 $-44.3MFY23 $-27.8MFY24 $-18.5MFY25 $-16.2M

EPS (Diluted)

—FY 2025

FY22 $-0.60FY23 —FY24 —FY25 —

Total Assets

+254.9% YoY

$13.0MFY 2025

FY22 $25.8MFY23 $7.3MFY24 $3.7MFY25 $13.0M

Total Debt

—FY 2025

FY22 $18.2MFY23 $18.3MFY24 —FY25 —

Op. Cash Flow

-32.7% YoY

$-14.1MFY 2025

FY22 $-39.8MFY23 $-21.7MFY24 $-10.6MFY25 $-14.1M

Free Cash Flow

—FY 2025

FY22 $-39.8MFY23 $-21.7MFY24 $-10.6MFY25 —

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$1.2M	$0.00	$0.00	—	—	—
Net Income	$-28.6M -13.9%	$-25.1M +16.7%	$-30.1M +24.2%	$-39.8M +57.3%	$-93.1M -8441.7%	$-1.1M
Operating Income	$-16.2M +12.3%	$-18.5M +33.5%	$-27.8M +37.2%	$-44.3M +61.7%	$-115.8M -12661.2%	$-907.4K
EPS (Diluted)	—	—	—	$-0.60 +69.7%	$-1.98 -31.1%	$-1.51
Total Assets	$13.0M +254.9%	$3.7M -50.1%	$7.3M -71.7%	$25.8M -21.1%	$32.7M +1012.8%	$2.9M
Total Debt	—	—	$18.3M +0.5%	$18.2M	—	—
Operating Cash Flow	$-14.1M -32.7%	$-10.6M +50.9%	$-21.7M +45.5%	$-39.8M -5.4%	$-37.7M -6198.4%	$-598.6K
Free Cash Flow	—	$-10.6M +50.9%	$-21.7M +45.5%	$-39.8M -5.4%	$-37.7M -6178.5%	$-600.6K

Get alerted when NRXP's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for NRX Pharmaceuticals, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of NRXP

B Group, Inc.
$16.7M4,091,767 sh
VANGUARD CAPITAL MANAGEMENT LLC
$6.6M1,618,159 sh
AMERIPRISE FINANCIAL INC
$3.8M928,728 sh
BALYASNY ASSET MANAGEMENT L.P.
$3.7M893,864 sh
CITADEL ADVISORS LLC
$2.8M680,043 sh
AdvisorShares Investments LLC
$2.7M659,018 sh
COMMONWEALTH EQUITY SERVICES, LLC
$1.9M454,418 sh
UBS Group AG
$1.7M423,115 sh
SIMPLEX TRADING, LLC
$1.3M317,800 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.3M314,659 sh

Fund	Value	Shares
B Group, Inc.	$16.7M	4,091,767
VANGUARD CAPITAL MANAGEMENT LLC	$6.6M	1,618,159
AMERIPRISE FINANCIAL INC	$3.8M	928,728
BALYASNY ASSET MANAGEMENT L.P.	$3.7M	893,864
CITADEL ADVISORS LLC	$2.8M	680,043
AdvisorShares Investments LLC	$2.7M	659,018
COMMONWEALTH EQUITY SERVICES, LLC	$1.9M	454,418
UBS Group AG	$1.7M	423,115
SIMPLEX TRADING, LLC	$1.3M	317,800
GEODE CAPITAL MANAGEMENT, LLC	$1.3M	314,659

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put NRXP on your watchlist

Track score changes the day NRX Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is NRXP a good stock to buy?

13F Pro's AI-powered analysis of NRX Pharmaceuticals, Inc. (NRXP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NRXP are available on the NRXP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. NRXP is classified as a small company.

Which hedge funds own NRXP?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NRXP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of NRX Pharmaceuticals, Inc.'s investment landscape.